MedPath

Comparison of DBS Targets in Obsessive-compulsive Disorder

Phase 3
Completed
Conditions
Obsessive-Compulsive Disorder
Registration Number
NCT01807403
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Deep brain stimulation (DBS) has been proposed for severe and resistant obsessive-compulsive disorder. This electrical stimulation has been tested on, and shown to be effective at, different targets (subthalamic nucleus, caudate nucleus \& nucleus accumbens). However, the efficacies of each target have never been compared directly.

This protocol aims to do so, with the hypothesis that subthalamic (STN) stimulation will be more efficacious.

Detailed Description

Deep brain stimulation has been proposed for severe and resistant obsessive-compulsive disorder (OCD). This electrical stimulation has been tested on, and shown to be effective at, different targets (subthalamic nucleus, caudate nucleus \& nucleus accumbens). However, the efficacies of each target have never been compared directly.

Therefore, bilateral subthalamic and caudate electrodes will be implanted in severe OCD patients. Efficacy of stimulation at the different targets will be assessed using a double-blind randomised crossover design.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Severity of symptoms after each phase3 months

Severity as measured by the Yale-Brown Obsession and Compulsion scale

Secondary Outcome Measures
NameTimeMethod
Severity of symptoms after each phase14 months

Severity as measured by the Yale-Brown Obsession and Compulsion scale

Trial Locations

Locations (1)

Centre d'investigation Clinique Pitié Salpêtrière

🇫🇷

Paris, France

Centre d'investigation Clinique Pitié Salpêtrière
🇫🇷Paris, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.